Salix Pharmaceuticals, Ltd. (SLXP) Reports Digestive Disease Week Update; XIFAXAN Investigated In Crohn's Disease And Small Bowel Bacterial Overgrowth
10/19/2005 5:10:00 PM
RALEIGH, N.C.--(BUSINESS WIRE)--May 18, 2005--Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today reported results of three investigator-initiated trials of XIFAXAN(TM) (rifaximin) tablets 200 mg that are being presented at Digestive Disease Week(R) 2005 (DDW) today. These posters are available for viewing from 8:00 a.m. until 5:00 p.m. today. The investigators have been requested to be present at their respective posters from 12:00 noon until 2:00 p.m.
Mild-Moderate Crohn's Disease
Dr. Asher Kornbluth, Associate Clinical Professor of Medicine at Mount Sinai School of Medicine, et al. conducted a trial in 30 Crohn's patients to assess the efficacy and tolerability of rifaximin in patients with mild-moderate Crohn's disease who had failed multiple baseline therapies. Rifaximin was dosed 600 mg daily (200mg TID) in 10 patients and 800 mg daily (400 mg BID) in 20 patients. Clinical outcome, assessed using the Present-Korelitz score, was dependent on disease location; 43% of patients with ileitis improved, 67% of patients with ileocolitis improved and 63% of patients with colitis improved. The only adverse event was oral thrush in 1 patient.